516 articles in this topic
A cancer patient on nivolumab developed Eikenella corrodens bacteremia after CNS infection, revealing how immune checkpoint therapy may enable dangerous microbial dissemination.
The FDA expanded accelerated approval for zongertinib in HER2-mutant NSCLC, marking a targeted therapy milestone for a hard-to-treat mutation.
Tissue stiffness triggers a chain reaction — recruiting macrophages that generate DNA-damaging lipid byproducts — linking fibrosis directly to cancer initiation.
Tumor cells in intrahepatic cholangiocarcinoma hijack IL-6 signaling to fuel growth — creating a targetable metabolic vulnerability.
Phase I trial of Temab-A reports 15.6% response rate and 74.6% disease control in heavily pretreated metastatic colorectal cancer patients.
A new DNA-based treatment blocks the PCSK9 protein, cutting LDL cholesterol by nearly 50% while avoiding common statin side effects.
A large WHO pharmacovigilance analysis reveals which myeloma drugs most strongly signal autonomic, motor, and sensory nerve damage.
Activated T cells release vesicles carrying genomic DNA that reprogram recipient cells to display tumor antigens more effectively.
Fibrotic tissue stiffness activates a cascade that recruits immune cells and generates DNA-damaging aldehydes, linking dense breast tissue to cancer risk.
Phase 1 trial shows MP0317 activates anti-tumor immunity in solid tumors with a favorable safety profile, supporting combination therapy.
RO7300490, a FAP-targeted CD40 agonist, proved manageable in 80 advanced cancer patients but produced no objective tumor responses despite clear immune activation.
A first-in-human trial shows CAR-modified stem cell memory T cells outperform standard CAR T cells in expansion, persistence, and complete responses.
